RNAIII-inhibiting peptide(TFA)

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus.

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. (In Vitro):RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/106 cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP.(In Vivo):RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin.

——

——

——

Others

Other Targets

Staphylococcus aureus

——

——

——

1027.01

C47H57F3N10O13

>98% (HPLC)

DMSO : ≥ 150 mg/mL (146.06 mM)

——

Sequence:Tyr-Ser-Pro-Trp-Thr-Asn-Phe

(-20℃)

With Ice Pack

≥ 2 years